Background: Systemic inflammation and nutritional status are key determinants of prognosis in metastatic clear-cell renal carcinoma (mccRCC). Composite indices such as the Systemic Immune–Inflammation Index (SII) and the Modified Glasgow Prognostic Score (mGPS) have demonstrated prognostic relevance across cancers, but real-world data in mccRCC remain limited. Methods: This retrospective, single-center cohort included patients with histologically confirmed mccRCC who received first-line tyrosine kinase inhibitor (TKI) monotherapy (sunitinib, pazopanib, or cabozantinib) between November 2022 and November 2024 at Etlik City Hospital (Ankara, Türkiye). Associations between inflammatory–nutritional indices (SII, mGPS) and progression-free survival (PFS) were evaluated using Kaplan–Meier and multivariable logistic regression analyses. Results: A total of 55 patients met eligibility criteria and were included in the analysis. The median age was 62 years (IQR 52–71), and 67% were male. Median PFS was 13.24 months (95% CI 7.75–19.12), while median OS was not reached. High SII (≥ 870) was independently associated with shorter PFS in multivariable analysis (OR 5.05; 95% CI 1.14–15.77; p = 0.039). mGPS (1–2) was significantly associated with inferior PFS in Kaplan–Meier analysis (HR 3.43; 95% CI 1.42–8.30; p = 0.006; log-rank p = 0.001), but lost significance in multivariable modeling. Metformin use (OR 0.12; 95% CI 0.02–0.93; p = 0.044), sunitinib therapy (OR 0.07; 95% CI 0.006–0.74; p = 0.027), and favorable/intermediate IMDC risk group (OR 0.17; 95% CI 0.06–0.96; p = 0.047) were independently associated with a lower progression risk. Patients treated with cabozantinib (n = 15) showed a numerically longer median PFS (18.6 months; 95% CI 13.8–23.3) compared with sunitinib (n = 25, 12.2 months; 95% CI 5.5–19.0) and pazopanib (n = 15, 12.1 months; 95% CI 6.7–17.5), although this difference was not statistically significant (log-rank p = 0.152). Conclusion: In this real-world cohort of patients with mccRCC treated with first-line TKI, host-related inflammatory and nutritional status were closely associated with progression-free survival. Additionally, patients classified within the favorable IMDC risk group exhibited a significantly lower risk of progression, highlighting the importance of integrating clinical risk stratification with systemic inflammatory and nutritional markers. Incorporating such easily measurable biomarkers and clinical risk scores into existing prognostic models may enhance individualized risk assessment and therapeutic decision-making. Future prospective, multicenter, randomized controlled, and artificial intelligence–assisted studies are warranted to validate these findings and refine precision oncology approaches in this population.
Predicting response to neoadjuvant therapy (NAT) remains a clinical challenge in patients with HER2-positive breast cancer (BC). Systemic inflammatory and immune-nutritional biomarkers have emerged as potential predictors of treatment response; however, their value in patients receiving dual anti-HER2 therapy is not well defined. This retrospective study included patients with HER2-positive BC treated with neoadjuvant dual anti-HER2 therapy between January 2023 and February 2025. A total of 136 patients were included. Pathological complete response (pCR) and radiological response assessed by positron emission tomography/computed tomography (PET/CT) were the primary outcomes. Routinely available inflammatory and immune-nutritional indices, including lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and C-reactive protein–to–albumin ratio (CAR), were evaluated using receiver operating characteristic analysis and multivariable logistic regression. Exploratory RF models were constructed to contextualize regression-based findings, with feature importance assessed using permutation importance and the Gini index. These machine learning analyses were conducted as exploratory, hypothesis-generating tools to support and contextualize regression-based findings rather than to establish standalone predictive models. Among 136 patients, 74% had locally advanced disease; pCR was achieved in 52.9%, and radiological response in 84.6%. Higher LMR (≥2.98) was independently associated with increased odds of pCR, whereas elevated SII and CAR were associated with reduced response. For radiological response, LMR, CAR, baseline CA 15–3 levels, and intermediate Ki-67 expression (20–30%) remained independently associated with outcomes. Exploratory machine-learning analyses consistently identified inflammatory and immune-nutritional biomarkers among the most influential predictors. Routinely available systemic inflammatory and immune-nutritional biomarkers, particularly LMR, SII, and CAR, are independently associated with pathological and radiological response to neoadjuvant dual anti-HER2 therapy in HER2-positive BC. These findings support the potential role of host-related biomarkers in treatment response prediction, pending prospective validation.